CYP2C19 Activity Assay, Catalog: MA-0220

Catalog MA-0220

Size 200 wells

Sample Type Human liver microsomes and liver S9 fractions, Lysates of tissues and cultured cells, primary hepatocytes, Heterologously expressed recombinant CYP2C19 preparations.

Method of Detection Fluorometric, Ex/Em = 406/468 nm

Assay Type Quantitative

Application A simple, sensitive means of assessing CYP2C19 activity in a variety of biological samples.

Storage Conditions -20°C

Shipping Temperature Gel Pack

Shelf Life One year from the date of delivery

CYP2C19, a member of the Cytochrome P450 superfamily, primarily expressed in liver, is responsible for the oxidative transformation of a number of clinically relevant drugs. Mutations of CYP2C19 can result in loss of function alleles (*2 or *3)  resulting in “poor metabolizers”, individuals with a reduced rate of drug metabolism or gain-of-function alleles (*17) resulting in rapid metabolizers. Clopidogrel, a drug used to prevent blood clots, is metabolized by CYP2C19 to its active form which inhibits platelet aggregation. A poor metabolizer is susceptible to adverse cardiovascular events such as stroke or heart attack, whereas a rapid metabolizer is susceptible to excessive bleeding complications. Similar circumstances are found with omeprazole and lansoprazole, where poor metabolizers have higher plasma concentrations resulting in enhanced side effects whereas, rapid metabolizers can experience reduced drug efficacy. Other drugs affected by CYP2C19 activity include citalopram, escitalopram and phenytoin where high or low rates of metabolism can have adverse effects. Knowing a patient’s CYP2C19 activity level is becoming an important data point for physicians in prescribing the correct dosage of a variety of medications. AkrivisBio’s CYP2C19 Assay is a simple, sensitive means of assessing CYP2C19 activity in a variety of biological samples.